Regulation of human nitric oxide synthase 2 expression by Wnt β-catenin signaling

Cancer Research

Volumn 66, Issue 14, 2006, Pages 7024-7031

  Du, Qiang ^a   Park, Kyung Soo ^a   Guo, Zhong ^a   He, Peijun ^b   Nagashima, Makoto ^b   Shao, Lifang ^a   Sahai, Rohit ^a   Geller, David A ^a   Hussain, S Perwez ^b  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CATENIN; CYTOKINE; GLYCOGEN SYNTHASE KINASE 3 INHIBITOR; INDUCIBLE NITRIC OXIDE SYNTHASE; LITHIUM CHLORIDE; MESSENGER RNA; NITRIC OXIDE; OLIGONUCLEOTIDE; PROTEIN ANTIBODY; T CELL FACTOR 4 BINDING ELEMENT 1; T CELL FACTOR 4 BINDING ELEMENT 2; T CELL FACTOR PROTEIN; UNCLASSIFIED DRUG; WNT PROTEIN;

ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; ENZYME REGULATION; GEL MOBILITY SHIFT ASSAY; GLYCOGEN SYNTHESIS; HUMAN; HUMAN CELL; LIVER CELL; MUTATIONAL ANALYSIS; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION;

ANIMALS; BETA CATENIN; CELL LINE, TUMOR; GLYCOGEN SYNTHASE KINASE 3; HCT116 CELLS; HUMANS; LITHIUM CHLORIDE; LIVER; MALE; NITRIC OXIDE SYNTHASE TYPE II; PROMOTER REGIONS (GENETICS); RATS; RATS, INBRED LEW; RNA, MESSENGER; SIGNAL TRANSDUCTION; TCF TRANSCRIPTION FACTORS; TRANS-ACTIVATION (GENETICS); TRANSFECTION; WNT PROTEINS;

EID: 33746864818     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-05-4110     Document Type: Article

References (49)

1. Ignarro LJ, Buga GM, Wood KS, Byrns RE, Chaudhuri G. Endothelium-derived relaxing factor produced and released from artery and vein is nitric oxide. Proc Natl Acad Sci U S A 1987;84:9265-9.
2. Ignarro LJ, Napoli C, Loscalzo J. Nitric oxide donors and cardiovascular agents modulating the bioactivity of nitric oxide: an overview. Circ Res 2002;90:21-8.
3. Bogdan C. Nitric oxide and the immune response. Nat Immunol 2001;2:907-16.
4. Hussain SP, Hofseth LJ, Harris CC. Radical causes of cancer. Nat Rev Cancer 2003;3:276-85.
5. Thomson LL, Scott JM, Topley P, Knowles RG, Keerie AJ, Frend AJ. Selective inhibition of inducible nitric oxide synthase inhibits tumor growth in vivo: studies with 1400W, a novel inhibitor. Cancer Res 1997;57:3300-4.
6. Crowell JA, Steele VE, Sigman CC, Fay JR. Is inducible nitric oxide synthase a target for chemoprevention? Mol Cancer Ther 2003;2:815-23.
7. Chung HT, Pae HO, Choi BM, Billiar TR, Kim YM. Nitric oxide as a bioregulator of apoptosis. Biochem Biophys Res Commun 2001;282:1075-9.
8. Hofseth LJ, Saito S, Hussain SP, et al. Nitric oxide-induced cellular stress and p53 activation in chronic inflammation. Proc Natl Acad Sci U S A 2003;100:143-8.
9. Lowenstein CJ, Alley EW, Raval P, et al. Macrophage nitric oxide synthase gene: two upstream regions mediate induction by interferon agamma; and lipopolysaccharide. Proc Natl Acad Sci U S A 1993;90:3730-4.
10. Xie QW, Whisnant R, Nathan C. Promoter of the mouse gene encoding calcium-independent nitric oxide synthase confers inducibility by interferon γ and bacterial lipopolysaccharide. J Exp Med 1993;177:1779-84.
11. Geller DA, Lowenstein CJ, Shapiro RA, et al. Molecular cloning and expression of inducible nitric oxide synthase from human hepatocytes. Proc Natl Acad Sci U S A 1993;90:3491-5.
12. de Vera ME, Shapiro RA, Nussler AK, et al. Transcriptional regulation of human inducible nitric oxide synthase (NOS2) gene by cytokines: initial analysis of the human NOS2 promoter. Proc Natl Acad Sci U S A 1996;93:1054-9.
13. Taylor BS, de Vera ME, Ganster RW, et al. Multiple NF-κB enhancer elements regulate cytokine induction of the human inducible nitric oxide synthase gene. J Biol Chem 1998;273:15148-56.
14. Feng X, Guo Z, Nourbakhsh M, et al. Identification of a negative response element in the human inducible nitric-oxide synthase (hiNOS) promoter: the role of NF-κB-repressing factor (NRF) in basal repression of the hiNOS gene. Proc Natl Acad Sci U S A 2002;99:14212-7.
15. Eissa NT, Yuan JW, Haggerty CM, Choo EK, Palmer CD, Moss J. Cloning and characterization of human inducible nitric oxide synthase splice variants: a domain, encoded by exons 8 and 9, is critical for dimerization. Proc Natl Acad Sci U S A 1998;95:7625-30.
16. Rodriguez-Pascual F, Hausding M, Ihrig-Biedert I, et al. Complex contribution of the 3′-untranslated region to the expressional regulation of the human inducible nitric-oxide synthase gene. Involvement of the RNA-binding protein HuR. J Biol Chem 2000;275:26040-9.
17. Griscavage JM, Rogers NE, Sherman MP, Ignarro LJ. Inducible nitric oxide synthase from a rat alveolar macrophage cell line is inhibited by nitric oxide. J Immunol 1993;151:6329-37.
18. Forrester K, Ambs S, Lupold SE, et al. Nitric oxide-induced p53 accumulation and regulation of inducible nitric oxide synthase (NOS2) expression by wild-type p53. Proc Natl Acad Sci U S A 1996;93:2442-7.
19. Ambs S, Ogunfusika MO, Merriam WG, Bennett WP, Billiar TR, Harris CC. Upregulation of NOS2 expression in cancer-prone p53 knockout mice. Proc Natl Acad Sci U S A 1998;95:8823-8.
20. Nusse R. Wnt signaling in disease and in development. Cell Res 2005;15:28-32.
21. Morin PJ. β-Catenin signaling and cancer. Bioessays 1999;21:1021-30.
22. He TC, Chan TA, Vogelstein B, Kinzler KW. PPARδ is an APC-regulated target of nonsteroidal anti-inflammatory drugs. Cell 1999;99:335-45.
23. -/- colon carcinoma. Science 1997;275:1784-7.
24. Morin PJ, Sparks AB, Korinek V, et al. Activation of β-catenin-Tcf signaling in colon cancer by mutations in β-catenin or APC. Science 1997;275:1787-90.
25. van de WM, Sancho E, Verweij C, et al. The β-catenin/TCF-4 complex imposes a crypt progenitor phenotype on colorectal cancer cells. Cell 2002;111:241-50.
26. Bowerman B. Cell biology. Oxidative stress and cancer: a β-catenin convergence. Science 2005;308:1119-20.
27. Essers MA, Vries-Smits LM, Barker N, Polderman PE, Burgering BM, Korswagen HC. Functional interaction between β-catenin and FOXO in oxidative stress signaling. Science 2005;308:1181-4.
28. Araki Y, Okamura S, Hussain SP, et al. Regulation of cyclooxygenase-2 expression by the wnt and ras pathways. Cancer Res 2003;63:728-34.
29. Komoroski BJ, Zhang S, Cai H, et al. Induction and inhibition of cytochromes P450 by the St. John's wort constituent hyperforin in human hepatocyte cultures. Drug Metab Dispos 2004;32:512-8.
30. Hussein SZ, Sneddon T, Tan X, Micsenyi A, Michalopoulos GK, Monga SP. Wnt impacts growth and differentiation in ex vivo liver development. Exp Cell Res 2004;292:157-69.
31. Towbin H, Staehelin T, Gordon J. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc Natl Acad Sci U S A 1979;76:4350-4.
32. Ganster RW, Taylor BS, Shao L, Geller DA. Complex regulation of human inducible nitric oxide synthase gene transcription by Stat 1 and NF-κB. Proc Natl Acad Sci U S A 2001;98:8638-43.
33. Warke VG, Nambiar ME Krishnan S, et al. Transcriptional activation of the human inducible nitric-oxide synthase promoter by Kruppel-like factor 6. J Biol Chem 2003;278:14812-9.
34. Geller DA, de Vera ME, Russell DA, et al. A central role for IL-1β in the in vitro and in vivo regulation of hepatic inducible nitric oxide synthase. IL-1β induces hepatic nitric oxide synthesis. J Immunol 1995;155:4890-8.
35. Tu Y, Wu S, Shi X, Chen K, Wu C. Migfilin and Mig-2 link focal adhesions to filamin and the actin cytoskeleton and function in cell shape modulation. Cell 2003;113:37-47.
36. He TC, Sparks AB, Rago C, et al. Identification of c-MYC as a target of the APC pathway. Science 1998;381:1509-12.
37. Ganster RW, Guo Z, Shao L, Geller DA. Differential effects of TNF-α and IFN-γ on gene transcription mediated by NF-κB-Stat1 interactions. J Interferon Cytokine Res 2005;25:707-19.
38. Levy L, Neuveut C, Renard CA, et al. Transcriptional activation of interleukin-8 by β-catenin-Tcf4. J Biol Chem 2002;277:42386-93.
39. Aberle H, Bauer A, Stappert J, Kispert A, Kemler R. β-Catenin is a target for the ubiquitin-proteasome pathway. EMBO J 1997;16:3797-804.
40. Hofseth LJ, Hussain SP, Wogan GN, Harris CC. Nitric oxide in cancer and chemoprevention. Free Radic Biol Med 2003;34:955-68.
41. Ambs S, Merriam WG, Bennett WP, et al. Frequent nitric oxide synthase-2 expression in human colon adenomas: implication for tumor angiogenesis and colon cancer progression. Cancer Res 1998;58:334-41.
42. Stamler JS, Singel DJ, Loscalzo J. Biochemistry of nitric oxide and its redox-activated forms. Science 1992;258:1898-902.
43. Middleton SJ, Shorthouse M, Hunter JO. Increased nitric oxide synthesis in ulcerative colitis. Lancet 1993;341:465-6.
44. Hussain SP, Amstad P, Raja K, et al. Increased p53 mutation load in noncancerous colon tissue from ulcerative colitis: a cancer-prone chronic inflammatory disease. Cancer Res 2000;60:3333-7.
45. Majano PL, Garcia-Monzon C, Lopez-Cabrera M, et al. Inducible nitric oxide synthase expression in chronic viral hepatitis. Evidence for a virus-induced gene upregulation. J Clin Invest 1998;101:1343-52.
46. Guo Z, Shao L, Feng X, et al. A critical role for C/EBPβ binding to the AABS promoter response element in the human iNOS gene. FASEB J 2003;17:1718-20.
47. Mellott JK, Nick HS, Waters MF, Billiar TR, Geller DA, Chesrown SE. Cytokine-induced changes in chromatin structure and in vivo footprints in the inducible NOS promoter. Am J Physiol Lung Cell Mol Physiol 2001;280: L390-9.
48. Marks-Konczalik J, Chu SC, Moss J. Cytokine-mediated transcriptional induction of the human inducible nitric oxide synthase gene requires both activator protein 1 and nuclear factor κB-binding sites. J Biol Chem 1998;273:22201-8.
49. Dash PR, Whitley GS, Ayling LJ, Johnstone AP, Cartwright JE. Trophoblast apoptosis is inhibited by hepatocyte growth factor through the Akt and β-catenin mediated up-regulation of inducible nitric oxide synthase. Cell Signal 2005;17:571-80.